Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6886 to 6900 of 7680 results

  1. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued [GID-TA11120]

  2. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued [GID-TA10356]

  3. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued [GID-TA10474]

  4. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

  5. Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy [ID1147]

    Discontinued [GID-TA10343]

  6. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued [GID-TA10473]

  7. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued [GID-TA10320]

  8. Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]

    Discontinued [GID-TA10401]

  9. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued [GID-TA10627]

  10. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

  11. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued [GID-TA10354]

  12. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued [GID-TA10480]

  13. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued [GID-TA10284]

  14. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued [GID-TA10166]

  15. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued [GID-TA10203]